Relafen 750, chemically known as naproxen, represents a important case study from a biochemical pharmacy standpoint. The drug exhibits its pain-relieving effect primarily by inhibiting the activity of cyclooxygenase (COX) enzymes, specifically COX-2, thereby limiting prostaglandin synthesis . The targeted inhibition of COX-2, compared to older NSAI